Clinical trials: Atypical Endometrial Hyperplasia
Endometrial Cancer
Surgery Plus Medroxyprogesterone in Preventing Endometrial Cancer
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of surgery with or without medroxyprogesterone may be an effective way to prevent the development…
- Trial name
- NCT00003179
- Testing
- medroxyprogesterone
- Where
- 31 sites in United States, Norway
- Volunteers
- 360 people
- Sponsor
- Gynecologic Oncology Group
Fertility-Sparing Treatment (FST), Atypical Endometrial Hyperplasia
Ultrasound and Histology in AEH and Early EEC Treated Conservatively
Ultra-S.A.F.E. is a multicenter, ambispective observational study investigating the ultrasound and histological characteristics of patients with atypical endometrial hyperplasia (AEH) or endometrioid endometrial carcinoma (EEC)…
- Conditions
- Fertility-Sparing Treatment (FST), Atypical Endometrial Hyperplasia, Early Endometrial Cancer (EEC)
- Trial name
- ULTRA-SAFE (NCT07028242)
- Testing
- Hysteroscopic fertility-sparing surgery and hormonal treatment
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Uterine Bleeding, Uterine Cancer
Measurement of Urinary Hormones in Patients With Abnormal Uterine Bleeding to Study Uterine Cancer Progression
The investigators will obtain urine hormone results and validated menstrual bleeding score from people experiencing abnormal uterine bleeding. The investigators will evaluate satisfaction and ease of use of Mira monitor.
- Conditions
- Uterine Bleeding, Uterine Cancer, Uterine Neoplasms, Endometrial Cancer
- Trial name
- MIRA (NCT07581288)
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- University of British Columbia
Atypical Endometrial Hyperplasia and Endometrial Cancer
Conservative Treatment for Atypical Endometrial Hyperplasia and Early Endometrial Cancer
Exploring the efficacy and pregnancy outcomes of conservative treatment for atypical endometrial hyperplasia and endometrial cancer. Study the factors related to predicting treatment efficacy.
- Trial name
- NCT06170684
- Volunteers
- 100 people
- Sponsor
- Beijing Obstetrics and Gynecology Hospital
Atypical Endometrial Hyperplasia, Progesterone Resistance
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients
To investigate the efficacy of Gonadotropin-releasing Hormone Agonist (GnRHa) plus letrozole in obese progestin-insensitive atypical endometrial hyperplasia (EAH) patients.
- Conditions
- Atypical Endometrial Hyperplasia, Progesterone Resistance, Obesity
- Trial name
- NCT06390904
- Testing
- GnRH antagonist, Letrozole 2.5mg
- Where
- 2 sites in China
- Volunteers
- 29 people
- Sponsor
- Xiaojun Chen
Endometrial Hyperplasia
Levonorgestrel-Releasing Intrauterine System (LNG-IUS) in the Management of Atypical Endometrial Hyperplasia
The purpose of this research study is to compare the uterus tissue of women who receive an intrauterine system to treat their endometrial hyperplasia with the uterine tissue of women who receive megestrol acetate to treat their…
- Trial name
- NCT04897217
- Testing
- Megestrol Acetate, Levonorgestrel Drug Implant
- Sponsor
- Wake Forest University Health Sciences
Endometrioid Endometrial Cancer, Atypical Endometrial Hyperplasia
Canagliflozin Plus Progestin for Atypical Endometrial Hyperplasia and Early-Stage Endometrial Cancer
This study aims to evaluate whether the addition of canagliflozin to levonorgestrel-releasing intrauterine system (LNG-IUS) treatment, as compared with matching placebo or with the addition of metformin, increases the rate of…
- Trial name
- NCT07890064
- Testing
- LNG-IUS: levonorgestrel intrauterine system, Metformin, Canagliflozin
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Wang Yingmei
Endometrial Hyperplasia Without Atypia
MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia
To compare the efficacy of Medroxyprogesterone Acetate with dydrogesterone in patients having endometrial hyperplasia (EH) without atypia.
- Trial name
- NCT03675139
- Testing
- Medroxyprogesterone Acetate, Dydrogesterone 10 MG
- Where
- China
- Volunteers
- 471 people
- Sponsor
- Xiaojun Chen
Endometrial Hyperplasia, Endometrial Cancer
Fertility Sparing Management of EndomeTrial Cancer and Hyperplasia
This study protocol evaluates the use of hysteroscopic endomyometrial resection in women diagnosed with atypical endometrial hyperplasia or grade I endometrial cancer who have not responded to anti-hormone therapy.
- Conditions
- Endometrial Hyperplasia, Endometrial Cancer, Gynecologic Cancer
- Trial name
- FETCH (NCT04362046)
- Testing
- Hysteroscopic uterine resection
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Vancouver Coastal Health Research Institute
Endometrioid Endometrial Adenocarcinoma
A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia
This study will explore the use of glucagon-like peptide 1 receptor agonist (GLP-1RA) used concurrently with levonorgestrel intrauterine device in patients with poor surgical candidacy for a hysterectomy or patients who are…
- Trial name
- NCT07107334
- Testing
- Glucagon-like peptide 1 receptor agonist
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Florida
Endometrial Carcinoma, Obesity
Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia
To assess the feasibility of an expedited referral process for the obese endometrial cancer or EIN patient from her gynecologic oncologist to the Brigham Center for Metabolic and Bariatric Surgery (CMBS) in order to undergo…
- Conditions
- Endometrial Carcinoma, Obesity, EIN, Endometrial Intraepithelial Neoplasia
- Trial name
- NCT04839614
- Testing
- CONCURRENT LAPAROSCOPIC HYSTERECTOMY AND WEIGHT LOSS SURGERY-Referral
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Atypical Endometrial Hyperplasia, Obesity
Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia
To study if polyethylene glycol loxenatide plus levonorgestrel-releasing intrauterine system (LNG-IUS) will improve response rates in patients with endometrial atypical hyperplasia.
- Conditions
- Atypical Endometrial Hyperplasia, Obesity, Fertility Issues
- Trial name
- NCT05172999
- Testing
- levonorgestrel-releasing intrauterine system, Polyethylene Glycol Loxenatide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Endometrial Hyperplasia, Endometrial Hyperplasia Without Atypia
Metformin for the Treatment of Endometrial Hyperplasia
The purpose of this study is to see if metformin will be effective in making endometrial hyperplasia without atypia better by returning the tissue to a normal state.
- Trial name
- NCT01685762
- Testing
- Metformin
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Endometrial Cancer, Atypical Hyperplasia
OSCAR ENDO One Stop Assessment of Risk for Endometrial Hyperplasia and Cancer
It is to be achieved that in postmenopausal women through the combination of Hysteroscopy and intraoperative rapid section a positive predictive value (PPV) regarding the objective illness like endometrial cancer or adenomatous…
- Trial name
- NCT01961102
- Testing
- hysteroscopy/curettage in case of suspicious aspect will be done a rapid section
- Where
- Austria
- Volunteers
- 300 people
- Sponsor
- Krankenhaus Barmherzige Schwestern Linz
Endometrial Hyperplasia Without Atypia
The Use of Etonogestrel Contraceptive Implant as Treatment for Endometrial Hyperplasia Without Atypia: A Cohort Study
Endometrial hyperplasia without atypia is a condition in which the endometrium (the lining of the uterus) becomes abnormally thick.
- Trial name
- NCT06378489
- Testing
- Etonogestrel implant
- Volunteers
- 60 people
- Sponsor
- University of the Philippines
Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I
Progesterone Therapeutic Regimen Plus Statins in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia
To explore the treatment efficacy of Progesterone Therapeutic Regimen Plus Statins in patients with atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EEC) for conservative treatment.
- Trial name
- NCT06102863
- Testing
- statins (oral atorvastatin calcium tablet 20mg/ day; Or rosuvastatin 5mg/ day; Or pivastatin 2mg/ day);
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Peking University People's Hospital
Endometrial Hyperplasia, Fertility Issues
A Pilot Study on Fertility Conservative Treatment of Atypical Endometrial Hyperplasia in Singapore
The investigators' objective is to determine the regression rate, side effects and acceptability of Mirena compared to megace in the treatment of atypical endometrial hyperplasia among women desiring fertility.
- Conditions
- Endometrial Hyperplasia, Fertility Issues, Disease Regression, Treatment Side Effects
- Trial name
- NCT05492487
- Testing
- Mirena, Megace
- Where
- 3 sites in Singapore
- Volunteers
- 60 people
- Sponsor
- KK Women's and Children's Hospital
Grade 1 Endometrial Endometrioid Carcinoma, Endometrial Intraepithelial Neoplasia
Tirzepatide and Levonorgestrel IUD Therapy for EIN and Early-Stage Endometrial Cancer
This single-arm study will evaluate the feasibility, safety, and preliminary efficacy of tirzepatide in combination with standard levonorgestrel intrauterine device (LNG-IUD) therapy in patients with endometrial intraepithelial…
- Conditions
- Grade 1 Endometrial Endometrioid Carcinoma, Endometrial Intraepithelial Neoplasia, Metabolic Comorbidities
- Trial name
- TIDE (NCT07812636)
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Milton S. Hershey Medical Center
Atypical Endometrial Hyperplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer
This randomized phase II trial studies how well levonorgestrel-releasing intrauterine system works when given alone or with everolimus in treating patients with atypical hyperplasia (a pre-cancerous growth of the lining of the…
- Conditions
- Atypical Endometrial Hyperplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
- Trial name
- LEVER (NCT02397083)
- Testing
- Everolimus, Laboratory Biomarker Analysis, Levonorgestrel-Releasing Intrauterine System
- Where
- 18 sites in United States
- Volunteers
- 102 people
- Sponsor
- M.D. Anderson Cancer Center
Endometrial Cancer, Fertility
Effect of Fertility-sparing Therapy of Early Endometrial Cancer
The purpose of this study is to investigate the effect of Fertility-sparing Therapy of Early Endometrial Cancer.
- Trial name
- ECFerSp (NCT03538704)
- Testing
- Metformin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking University People's Hospital